DE60113733T2 - Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren - Google Patents

Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren Download PDF

Info

Publication number
DE60113733T2
DE60113733T2 DE60113733T DE60113733T DE60113733T2 DE 60113733 T2 DE60113733 T2 DE 60113733T2 DE 60113733 T DE60113733 T DE 60113733T DE 60113733 T DE60113733 T DE 60113733T DE 60113733 T2 DE60113733 T2 DE 60113733T2
Authority
DE
Germany
Prior art keywords
cyclopamine
cells
bcc
tumor
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60113733T
Other languages
German (de)
English (en)
Other versions
DE60113733D1 (de
Inventor
Sinan Tas Dr.
Avci Dr.Oktay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tas Sinan Bor Tr
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60113733(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60113733D1 publication Critical patent/DE60113733D1/de
Publication of DE60113733T2 publication Critical patent/DE60113733T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60113733T 2001-07-02 2001-07-02 Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren Expired - Lifetime DE60113733T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (2)

Publication Number Publication Date
DE60113733D1 DE60113733D1 (de) 2006-02-09
DE60113733T2 true DE60113733T2 (de) 2006-06-29

Family

ID=21619326

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60113733T Expired - Lifetime DE60113733T2 (de) 2001-07-02 2001-07-02 Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
DE60204966T Expired - Lifetime DE60204966T2 (de) 2001-07-02 2002-04-19 Verwendung von Cyclopamin zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60204966T Expired - Lifetime DE60204966T2 (de) 2001-07-02 2002-04-19 Verwendung von Cyclopamin zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis

Country Status (14)

Country Link
EP (4) EP2862570A1 (OSRAM)
JP (3) JP2004536045A (OSRAM)
KR (1) KR20090125833A (OSRAM)
CN (2) CN1525859B (OSRAM)
AT (2) ATE305300T1 (OSRAM)
AU (1) AU2001272892B8 (OSRAM)
BR (1) BR0117063A (OSRAM)
CA (1) CA2452151C (OSRAM)
DE (2) DE60113733T2 (OSRAM)
DK (2) DK1401438T3 (OSRAM)
ES (3) ES2534400T3 (OSRAM)
PT (1) PT1411938E (OSRAM)
RU (1) RU2312661C2 (OSRAM)
WO (2) WO2002078703A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
EP2511298B1 (en) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Compositions and Methods for Treating Cancer based on human FZD receptors
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2008070357A2 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008109184A1 (en) * 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
JP2010520310A (ja) * 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド シクロパミンラクタム類似体及びその使用方法
CN104059124A (zh) 2007-12-27 2014-09-24 无限药品股份有限公司 立体选择性还原的方法
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011123785A2 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
HRP20251395T1 (hr) 2015-06-04 2026-02-13 Sol-Gel Technologies Ltd. Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CN117940170A (zh) 2021-09-13 2024-04-26 辛南·塔斯 有效干预人类衰老和衰老疾病及其效果
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
CA2326654C (en) * 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
RU2232758C2 (ru) * 1998-09-23 2004-07-20 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
CA2386190C (en) * 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
AU1935801A (en) * 1999-11-30 2001-06-12 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
EP2862570A1 (en) * 2001-07-02 2015-04-22 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Also Published As

Publication number Publication date
CA2452151C (en) 2012-01-03
EP1401438B1 (en) 2005-09-28
EP1401438A1 (en) 2004-03-31
PT1411938E (pt) 2005-11-30
DE60204966T2 (de) 2006-05-18
WO2002078703A1 (en) 2002-10-10
CN1525859B (zh) 2010-05-05
JP2014028834A (ja) 2014-02-13
DK1411938T3 (da) 2005-11-07
WO2002078703A8 (en) 2003-06-12
DK1401438T3 (da) 2006-02-13
EP2216022A1 (en) 2010-08-11
ES2250434T3 (es) 2006-04-16
EP2862570A1 (en) 2015-04-22
AU2001272892B8 (en) 2006-05-04
ATE299022T1 (de) 2005-07-15
WO2002078704A1 (en) 2002-10-10
DE60204966D1 (de) 2005-08-11
EP1561464A2 (en) 2005-08-10
RU2312661C2 (ru) 2007-12-20
CN1230169C (zh) 2005-12-07
EP2216022B1 (en) 2015-01-07
CN1522146A (zh) 2004-08-18
EP1561464A3 (en) 2007-04-25
DE60113733D1 (de) 2006-02-09
BR0117063A (pt) 2004-07-27
ES2534400T3 (es) 2015-04-22
ATE305300T1 (de) 2005-10-15
CA2452151A1 (en) 2002-10-10
RU2004103074A (ru) 2005-05-10
KR20090125833A (ko) 2009-12-07
ES2246011T3 (es) 2006-02-01
JP2010132691A (ja) 2010-06-17
JP5424923B2 (ja) 2014-02-26
AU2001272892B2 (en) 2006-03-16
JP2004536045A (ja) 2004-12-02
CN1525859A (zh) 2004-09-01

Similar Documents

Publication Publication Date Title
DE60302348T2 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
DE69323549T2 (de) Topisch anwendbare arzneimittel, enthaltend toremifen und dessen metabolite
DE60204966T2 (de) Verwendung von Cyclopamin zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
DE2746950C2 (OSRAM)
DE69327544T2 (de) Mischungen zum schutz und regenierung von geweben
DE69635488T2 (de) Antivirale verbindung
AU2001272892A1 (en) Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
DE69215999T2 (de) Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs
DE69902520T2 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE69917796T2 (de) Decursin-enthaltende pharmazeutische zusammensetzungen
EP1056467B1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
DE1804801B2 (de) Mittel zur aknebehandlung
DE69727154T2 (de) Land- und meeressschildkrötenöle, diese enthaltende zusammensetzungen, verfahren zu deren herstellung und verwendungen
DE69607854T2 (de) Sphingosylphosphorylcholin als wirkstoff zur wundheilung
DE60035613T2 (de) Topische,kosmetische und pharmazeutische Mittel,enthaltend spezifische alkoxylierte Diester der Fumarsäure
DE3633315A1 (de) Mittel zur prophylaxe und behandlung von hautverbrennungen durch strahlen
DE69934336T2 (de) Verwendung von halofuginone zur behandlung von urethralstriktur
WO2023084038A1 (de) Selbstemulgierende öl-in wasser-mikro- oder nanoemulsion sowie emulgierende zusammensetzung
DE102013104342A1 (de) Pharmazeutische Zusammensetzung
DE69735091T2 (de) Synergistische Gold enthaltende Zusammensetzungen
Wahba et al. A Comparative Study between the Combined Effect of Frankincense and Myrrh versus the Effect of Triamcinolone Acetonide on Healing of Induced Labial Mucosal Ulcer in Albino Rats
DE19853425A1 (de) Khellin-Zubereitung und deren Verwendung zur topischen Therapie der Psoriasis, ihrer Subtypen, Sonderformen, sowie zur topischen Therapie von Ekzemen
DE2713105A1 (de) Dermatologisches arzneimittel
LU84952A1 (de) Arzneimittel mit analgetischer wirkung
EP1633374A1 (de) Zusammensetzung aus alkandicarbonsäuren und einem pharmazeutischen wirkstoff

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: TAS, SINAN, BOR, TR